Rolf H. Sijmons

Rolf H. Sijmons

Auto-generated profile, based on publicly available information

Rolf H. Sijmons

Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1997 in Human Molecular Genetics
Verified
Journal Article
Closed access
MNM R Nelen
M R Nelen
WSW C Van Staveren
W C Van Staveren
EPE A Peeters
E A Peeters
MHM B Hassel
M B Hassel
RGR J Gorlin
R J Gorlin
HKH Kremer
H Kremer
Cowden disease, also known as multiple hamartoma syndrome, is an autosomal dominant cancer syndrome with a high risk of breast and thyroid cancer. The gene involved has been localized to chromosome 10q22-23. Recently, the tumour suppressor gene PTEN/MMAC1, encoding a putative protein tyrosine or dual-specificity phosphatase, was cloned from that region and three mutations were detected in patients with Cowden disease. We confirmed that the PTEN/MMAC1 gene is indeed the gene for Cowden disease by a refined localization of the gene to the interval between D10S1761 and D10S541, which contains the PTEN/MMAC1 gene and, by mutation analysis in eight unrelated familial and 11 sporadic patients with Cowden disease. Eight different mutations were detected in various regions of the PTEN/MMAC1 gene. One mutation was detected twice. All detected changes in the gene can be predicted to have a very deleterious effect on the putative protein. Five of the nine patients have a mutation in exon 5 coding for the putative active site and flanking amino acids. Evaluation of the clinical data of the patients in which a mutation could be detected gives no clear indications for a correlation between the genotype and phenotype. In 10 patients no mutation could be detected so far. In support of the linkage data, no evidence has emerged from the phenotype of these patients suggestive for genetic heterogeneity.

1 October 1999 in Nature Genetics
Verified
Journal Article
Closed access
JWJuul Wijnen
Juul Wijnen
WLWiljo de Leeuw
Wiljo de Leeuw
THThomas Hansen
Thomas Hansen
HKHeleen van der Klift
Heleen van der Klift
PMPål Møller
Pål Møller
Riccardo FoddeRiccardo Fodde
Riccardo Fodde

20 August 1998 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
JWJuul T. Wijnen
Juul T. Wijnen
THThomas Hansen
Thomas Hansen
PKP. Meera Khan
P. Meera Khan
AZAeilko H. Zwinderman
Aeilko H. Zwinderman
HKHeleen van der Klift
Heleen van der Klift
PGPetr Goetz
Petr Goetz
Germ-line mutations in DNA mismatch-repair genes (MSH2, MLH1, PMS1, PMS2, and MSH6 ) cause susceptibility to hereditary nonpolyposis colorectal cancer. We assessed the prevalence of MSH2 and MLH1 mutations in families suspected of having hereditary nonpolyposis colorectal cancer and evaluated whether clinical findings can predict the outcome of genetic testing. We used denaturing gradient gel electrophoresis to identify MSH2 and MLH1 mutations in 184 kindreds with familial clustering of colorectal cancer or other cancers associated with hereditary nonpolyposis colorectal cancer. Information on the site of cancer, the age at diagnosis, and the number of affected family members was obtained from all families. Mutations of MSH2 or MLH1 were found in 47 of the 184 kindreds (26 percent). Clinical factors associated with these mutations were early age at diagnosis of colorectal cancer, the occurrence in the kindred of endometrial cancer or tumors of the small intestine, a higher number of family members with colorectal or endometrial cancer, the presence of multiple colorectal cancers or both colorectal and endometrial cancers in a single family member, and fulfillment of the Amsterdam criteria for the diagnosis of hereditary nonpolyposis colorectal cancer (at least three family members in two or more successive generations must have colorectal cancer, one of whom is a first-degree relative of the other two; cancer must be diagnosed before the age of 50 in at least one family member; and familial adenomatous polyposis must be ruled out). Multivariate analysis showed that a younger age at diagnosis of colorectal cancer, fulfillment of the Amsterdam criteria, and the presence of endometrial cancer in the kindred were independent predictors of germ-line mutations of MSH2 or MLH1. These results were used to devise a logistic model for estimating the likelihood of a mutation in MSH2 and MLH1. Assessment of clinical findings can improve the rate of detection of mutations of DNA mismatch-repair genes in families suspected of having hereditary nonpolyposis colorectal cancer.

1 June 2010 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
MRMarielle W G Ruijs
Marielle W G Ruijs
SVSenno Verhoef
Senno Verhoef
MRM. A. Rookus
M. A. Rookus
RPRoelof Pruntel
Roelof Pruntel
AHAnnemarie H van der Hout
Annemarie H van der Hout
LVLaura J van 'T Veer
Laura J van 'T Veer
Background Li–Fraumeni syndrome (LFS) is a rare autosomal dominant cancer predisposition syndrome. Most families fulfilling the classical diagnostic criteria harbour TP53 germline mutations. However, TP53 germline mutations may also occur in less obvious phenotypes. As a result, different criteria are in use to decide which patients qualify for TP53 mutation analysis, including the LFS, Li–Fraumeni-like (LFL) and Chompret criteria. We investigated which criteria for TP53 mutation analysis resulted in the highest mutation detection rate and sensitivity in Dutch families. We describe the tumour spectrum in TP53-positive families and calculated tumour type specific relative risks. Method A total of 180 Dutch families referred for TP53 mutation analysis were evaluated. Tumour phenotypes were verified by pathology reports or clinical records. Results A TP53 germline mutation was identified in 24 families. When the Chompret criteria were used 22/24 mutations were detected (sensitivity 92%, mutation detection rate 21%). In LFS and LFL families 18/24 mutations were found (sensitivity 75%). The two mutations detected outside the ‘Chompret group’ were found in a child with rhabdomyosarcoma and a young woman with breast cancer. In the mutation carriers, in addition to the classical LFS tumour types, colon and pancreatic cancer were also found significantly more often than in the general population. Conclusion We suggest TP53 mutation testing for all families fulfilling the Chompret criteria. In addition, TP53 mutation testing can be considered in the event of childhood sarcoma and breast cancer before 30 years. In addition to the risk for established LFS tumour types, TP53-positive individuals may also have an elevated risk for pancreatic and colon cancer.

1 January 2011 in The Lancet Oncology
Verified
Journal Article
Closed access
MKMarlies Je Kempers
Marlies Je Kempers
RKRoland P Kuiper
Roland P Kuiper
COCharlotte W Ockeloen
Charlotte W Ockeloen
PCPierre O Chappuis
Pierre O Chappuis
PHPierre Hutter
Pierre Hutter
MLMarjolijn Jl Ligtenberg
Marjolijn Jl Ligtenberg

1 November 1999 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
YWYing Wu
Ying Wu
MBMaran J.W. Berends
Maran J.W. Berends
RMRob G.J. Mensink
Rob G.J. Mensink
CKClaudia Kempinga
Claudia Kempinga
RSRolf H. Sijmons
Rolf H. Sijmons
RHRobert M.W. Hofstra
Robert M.W. Hofstra